Androgen deprivation therapy (ADT) causes hot flushes that can disrupt an individual's quality of life. NK3R antagonists provide rapid, sustained, and nonhormonal relief of hot flushes in women, but an approved treatment is lacking for men.
Pragmatic trials are needed to generate evidence to support approval of these agents for the ADT setting.
European urology. 2025 Dec 13 [Epub ahead of print]
Martino Pedrani, Silke Gillessen, Erik Briers, Pierre Blanchard, Anthony M Joshua, Bertrand Tombal
Istituto Oncologico della Svizzera Italiana, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Electronic address: ., Istituto Oncologico della Svizzera Italiana, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Europa Uomo European Prostate Cancer Coalition, Antwerp, Belgium., Oncostat U1018 Inserm, Department of Radiation Oncology, Université Paris-Saclay, Gustave-Roussy, Villejuif, France., Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; School of Clinical Medicine, University of New South Wales, Sydney, Australia., Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Brussels, Belgium.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/41392000